Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
HRAS Q61L PLX7904 skin squamous cell carcinoma no benefit detail...
Unknown unknown R11.1.6 skin squamous cell carcinoma not applicable detail...
Unknown unknown Pembrolizumab skin squamous cell carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02324608 Phase I Cetuximab Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer Recruiting
NCT02449681 Phase II TH-4000 Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS Terminated
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting
NCT02760498 Phase II Cemiplimab Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Recruiting
NCT02964559 Phase II Pembrolizumab Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Active, not recruiting
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting
NCT03108131 Phase II Atezolizumab + Cobimetinib Cobimetinib and Atezolizumab in Advanced Rare Tumors Recruiting
NCT03284424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) Active, not recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03524326 Phase I Cetuximab + Lenvatinib Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma Recruiting
NCT03539198 Phase 0 Nivolumab Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer Recruiting
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Recruiting
NCT03816332 Phase I Ipilimumab + Nivolumab + Prednisone + Tacrolimus Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Recruiting
NCT03833167 Phase III Pembrolizumab Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) Recruiting
NCT03871348 Phase I SAR441000 Cemiplimab + SAR441000 A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Recruiting
NCT03889912 Phase I Cemiplimab Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma Recruiting
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting
NCT03901573 Phase Ib/II Atezolizumab + NT-I7 High-Risk Skin Cancers With Atezolizumab Plus NT-I7 Recruiting
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Active, not recruiting
NCT03944941 Phase II Avelumab Avelumab + Cetuximab Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer Recruiting
NCT03969004 Phase III Cemiplimab Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Recruiting
NCT04050436 Phase II Cemiplimab + RP1 RP1 Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) Recruiting
NCT04105543 Phase I CLR 131 CLR 131 Combined With Radiation for Head and Neck Cancer Recruiting
NCT04154943 Phase II Cemiplimab Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma Recruiting
NCT04160065 Phase I IFx-Hu2.0 Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC Recruiting
NCT04163952 Phase I Panitumumab + Talimogene laherparepvec Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Recruiting
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Not yet recruiting
NCT04293679 Phase Ib/II STP705 Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC Recruiting
NCT04315701 Phase II Cemiplimab A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer Not yet recruiting
NCT04339062 Phase I Cemiplimab Cemiplimab + Everolimus + Prednisone Cemiplimab + Prednisone + Sirolimus Cemiplimab in AlloSCT/SOT Recipients With CSCC (CONTRAC) Recruiting
NCT04389632 Phase I A Study of SGN-B6A in Advanced Solid Tumors Recruiting
NCT04428671 Phase I Cemiplimab Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer Recruiting